TQB3019

TQB3019 is an orally available **proteolysis-targeting chimera (PROTAC)** developed to degrade **Bruton's tyrosine kinase (BTK)** via the ubiquitin-proteasome pathway. As a heterobifunctional molecule, it binds both BTK proteins and E3 ubiquitin ligases, leading to targeted degradation of BTK, which inhibits BTK-mediated downstream signaling and thereby suppresses tumor growth. This approach is designed to overcome resistance mechanisms seen with classical BTK inhibitors. TQB3019 was developed using the OAPD® (Orally Available Protein Degrader) platform. Preclinical studies indicate potent anti-tumor efficacy—including against BTK wild-type and drug-resistant mutants—good safety, and a clear mechanism of action. It is intended primarily for treatment of hematological malignancies and advanced solid tumors, and is currently undergoing Phase 1 clinical trials in China[1][2][3][10].